

Product Data Sheet

Product Name: Vipadenant

Cat. No.: GC19376

Chemical Properties

Cas. No. 442908-10-3

SMILES NC1=NC2=C(N=NN2CC3=CC=C(N)C(C)=C3)C(C4=CC=CO4)=N1


Formula $C_{16}H_{15}N_7O$ M.Wt 321.34

Solubility DMSO : ≥ 31 mg/mL (96.47 mM) Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37°C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure



Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Background

Vipadenant is an adenosine receptor antagonist, with K_{is} of 1.3 nM and 68 nM for A_{2A} and A₁, respectively.

Vipadenant (0.3-30 mg/kg) produces a dose-dependent reduction in catalepsy. Vipadenant (10 mg/kg) does not produce any statistically significant dyskinetic episodes in 6-OHDA-lesioned rats during a 19-day dosing regimen[1]. In the mouse and rat haloperidol-induced hypolocomotion models, vipadenant has a minimum effective dose of 0.1 and 1 mg/kg, respectively. Vipadenant (3 and 10 mg/kg, p.o.) is able to increase contralateral rotations in 6-OHDA lesioned rats[2].

References:

- [1]. Jones N, et al. A_{2A} receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats. Brain Res Bull. 2013 Sep;98:163-9.
- [2]. Brian C. Shook, et al. Adenosine A_{2A} Receptor Antagonists and Parkinson's Disease. ACS Chem Neurosci. 2011 Oct 19; 2(10): 555-567.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA